← 返回首页
美国 · 经济杂志 · Quartz

Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

来源:Quartz · 美国 25 分钟前
Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront
Quartz

详细摘要

Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324

在 Quartz 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (qz.com)

推荐阅读